Summary:
Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy.
Inclusion Criteria:
1. Male or female, aged 18 to 74 years of age, inclusive.
2. Be medically stable on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening and baseline.
3. Meet DSM-5 diagnostic criteria for recurrent or single episode MDD, without psychotic features.
4. Is currently receiving and tolerating well on any of the SSRI or SNRI for depressive symptoms.
Qualified Participants May Receive:
Free study related care and compensation up to $1,050 for time and travel.